Articles
This is a partial listing of articles on this site (see the Latest/Articles by Date page for all articles).
General Articles
- An Introduction to Hormone Therapy for Transfeminine People (Aly W., 2018)
- An Exploration of Possibilities for Hormone Therapy in Non-Binary Transfeminine People (Aly W., 2019)
- Puberty Blockers: A Review of GnRH Analogues in Transgender Youth (Mitzi, 2022)
Special Topics
Estrogens
- Oral versus Transdermal Estradiol in Feminising Hormone Therapy for Transgender Individuals (Sam S., 2020)
- An Exploration of Sublingual Estradiol as an Alternative to Oral Estradiol in Transfeminine People (Sam S., 2021)
- Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People (Aly W., 2019)
- A Review of Studies on Estradiol Levels and Testosterone Suppression with High-Dose Transdermal Estradiol Gel and Ointment in Cisgender Men with Prostate Cancer (Aly W., 2019)
- Genital Application via the Scrotum and Neolabia for Greatly Enhanced Absorption of Transdermal Estradiol in Transfeminine People (Aly W., 2019)
- An Interactive Web Simulator for Estradiol Levels with Injectable Estradiol Esters (Aly W., 2021)
- An Informal Meta-Analysis of Estradiol Curves with Injectable Estradiol Preparations (Aly W., 2021)
- Estrogens and Their Influences on Coagulation and Risk of Blood Clots (Aly W., 2020)
- The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy (Aly W., 2020)
Antiandrogens
- Low Doses of Cyproterone Acetate Are Maximally Effective for Testosterone Suppression in Transfeminine People (Aly W., 2019)
- Recent Developments on Cyproterone Acetate and Meningioma Risk Out of France and Implications for Transfeminine People (Aly W., 2020)
- Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy (Aly W., 2020)
- Information on Bicalutamide (Casodex) as an Antiandrogen for Transfeminine People (Aly W., 2018)
- Bicalutamide: Frequently Asked Questions and Common Misconceptions (Aly W., 2018)
- Buserelin, a Gonadotropin-Releasing Hormone Agonist, is Inexpensively Available as a Nasal Spray From Online Pharmacies (Aly W., 2018)
Progestogens
- Oral Progesterone Achieves Very Low Levels of Progesterone and Has Only Weak Progestogenic Effects (Aly W., 2018)
- Administration of Oral Progesterone Capsules Rectally Instead of Orally for Greatly Improved Efficacy in Transfeminine People (Aly W., 2018)
- The Influence of Progesterone and Other Progestogens on Sexual Desire and Function (Aly W., 2020)
- Progesterone and its Role in Breast Development During Female Puberty (Aly W., 2020)
- Progestogens and Breast Cancer in Transgender Women: A Review and Discussion of Risk (Sam S., 2020)
Other Medications
- A Review of Selective Estrogen Receptor Modulators and their Potential for Transfeminine Hormone Therapy (Lain M., 2019)
- Nandrolone as an Alternative Androgen with Reduced Androgenic Side Effects for Transfeminine and Transmasculine People (Aly W., 2020)
General Effects and Risks
- On Changes in Bone Shape in Transfeminine Individuals Under Gender-Affirming Hormone Therapy (Lain M., 2020)
- On the Impact of Sex Hormones on Fat Metabolism with an Eye Towards Transfeminine Hormone Therapy (Lain M., 2019)
- The Relationship Between the Endocrine System and Muscle Mass (Lain M., 2019)
- Breast Cancer Risk with Hormone Therapy in Transfeminine People (Aly W., 2020)
Miscellaneous
- Injectable Aqueous Suspensions of Sex Hormones and How Depot Injectables Work (Aly W., 2019)
- Commentary and Fact Check of Dr. Will Powers’s Transgender Care Presentation (Aly W., 2019)
- The Roles of Placebo and Nocebo in Medication Effects and Why Subjective Reports Are Unreliable (Aly W., 2020)
- Prenatal Diethylstilbestrol Exposure and Likelihood of Being Transgender (Aly W., 2020)
Data, Analysis, and Literature
- Clinical Guidelines with Information on Transfeminine Hormone Therapy (Aly W., 2020)
- Approximate Comparable Dosages of Estradiol by Different Routes (Aly W., 2020)
- Hormone Levels During Normal Puberty in Cisgender Girls (Aly W., 2020)
- Analysis of Estradiol and Testosterone Levels with Oral Estradiol in Transfeminine People Based on Leinung et al. (2018) (Aly W., 2019)
- Analysis of Cardiovascular and Thromboembolic Toxicity with High Dose Parenteral Polyestradiol Phosphate in the Treatment of Prostate Cancer (Sam S., 2020)
- Analysis of Studies Assessing the Risk of Thromboembolism with Transfeminine Hormone Therapy (Sam S., 2020)
- Published Literature on Bicalutamide as an Antiandrogen for Transfeminine People (Aly W., 2019)
- Excerpts: Perspectives and Opinions of Clinicians and Researchers Concerning the Use of Progestogens in Transfeminine Hormone Therapy (Sam S., 2020)
- Published Case Reports of Lactation and/or Breastfeeding in Transfeminine People (Aly W., 2019)
- Excerpts: Early Progestogen Exposure May Result in Suboptimal Breast Development (Aly W., 2019)
- Data Show That the Number of People Hormonally Transitioning has Skyrocketed in Recent Years (Aly W., 2019)
Drug Research and New Approvals
- EC508 (Estradiol Aminosulfonylbenzoylproline), a Unique and Highly Promising Estradiol Ester and Possible Oral Estradiol Form of the Future (Aly W., 2018)
- Approval of Elagolix (Orilissa), the first Orally Active Gonadotropin-Releasing Hormone Antagonist, and Relevance for Transfeminine People (Aly W., 2018)
- Approval of Relugolix (Relumina), the Second Orally Active GnRH Antagonist, and Relevance for Transfeminine People (Aly W., 2019)
- Darolutamide (Nubeqa), a New Second-Generation Nonsteroidal Antiandrogen, Has Been Approved for Medical Use (Aly W., 2019)
- A Drospirenone Progestogen-Only Birth Control Pill (Slynd) Has Been Introduced in the United States and Europe: Potential Use in Transfeminine Hormone Therapy (Aly W., 2019)